Giuseppe Suanno

Dr. Giuseppe Suanno

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Experimental Eye Research
Verified
Journal Article
Closed access
GSGiuseppe Suanno
Giuseppe Suanno
PFPhilippe Fonteyne
Philippe Fonteyne
GFGiulio Ferrari
Giulio Ferrari

26 March 2023 in Cells
Verified
Journal Article
Open access
PDF file
PFPaola Fabbrizio
Paola Fabbrizio
CMCassandra Margotta
Cassandra Margotta
JDJessica D'Agostino
Jessica D'Agostino
GSGiuseppe Suanno
Giuseppe Suanno
LQLorenzo Quetti
Lorenzo Quetti
Giovanni NARDOGiovanni NARDO
Giovanni NARDO
Amyotrophic Lateral Sclerosis (ALS) is the most common adult motor neuron disease, with a poor prognosis, a highly unmet therapeutic need, and a burden on health care costs. Hitherto, strategies aimed at protecting motor neurons have missed or modestly delayed ALS due to a failure in countering the irreversible muscular atrophy. We recently provided direct evidence underlying the pivotal role of macrophages in preserving skeletal muscle mass. Based on these results, we explored whether the modulation of macrophage muscle response and the enhancement of satellite cell differentiation could effectively promote the generation of new myofibers and counteract muscle dysfunction in ALS mice. For this purpose, disease progression and the survival of SOD1G93A mice were evaluated following IL-10 injections in the hindlimb skeletal muscles. Thereafter, we used ex vivo methodologies and in vitro approaches on primary cells to assess the effect of the treatment on the main pathological signatures. We found that IL-10 improved the motor performance of ALS mice by enhancing satellite cells and the muscle pro-regenerative activity of macrophages. This resulted in delayed muscle atrophy and motor neuron loss. Our findings provide the basis for a suitable adjunct multisystem therapeutic approach that pinpoints a primary role of muscle pathology in ALS.

15 April 2025 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
NBNicolò Bartolomeo
Nicolò Bartolomeo
MPMatteo Pederzolli
Matteo Pederzolli
SPSilvia Palombella
Silvia Palombella
PFPhilippe Fonteyne
Philippe Fonteyne
GSGiuseppe Suanno
Giuseppe Suanno
GFGiulio Ferrari
Giulio Ferrari

25 November 2023 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
GSGiuseppe Suanno
Giuseppe Suanno
MPMatteo Pederzolli
Matteo Pederzolli
RVRomina Mayra Lasagni Vitar
Romina Mayra Lasagni Vitar
PFPhilippe Fonteyne
Philippe Fonteyne
GFGiulio Ferrari
Giulio Ferrari
To assess whether topical administration of fosaprepitant improves intractable chronic ocular pain and inflammation. We report three clinical cases of female patients with drug-resistant ocular pain associated with inflammatory diseases of the ocular surface. The patients were treated for 3 (case 1) and 4 (cases 2–3) weeks with fosaprepitant eyedrops (0.1 mg/mL for case 1; 10 mg/mL for case 2–3). Patients were then followed up for at least 3 weeks. We measured ocular pain with the Visual Analogue Scale (VAS), the Ocular Surface Disease Index (OSDI), and corneal sensitivity with the Cochet-Bonnet esthesiometry. Slit-lamp photography and corneal confocal imaging were used to assess ocular surface integrity/conjunctival hyperemia and corneal nerve morphology, respectively. All three patients had severe ocular pain (score higher than 6/10 VAS scale). All patients reported a significant improvement in ocular pain after 1 week of treatment. We also observed reduced corneal epitheliopathy (case 1) and conjunctival hyperemia (cases 1–2). In two patients (cases 2–3) the treatment was repeated after 1 year and 9 weeks, respectively, and pain reduction was similar in magnitude to what we observed after the first administration. Topical administration of fosaprepitant ameliorates ocular pain and clinical symptoms in three patients with intractable ocular pain associated with inflammatory diseases of the ocular surface, without adverse effects. Fosaprepitant instillation holds promise as a treatment of chronic ocular pain, an area of unmet medical need.

2 March 2026 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
GSGiuseppe Suanno
Giuseppe Suanno
PFPhilippe Fonteyne
Philippe Fonteyne
MMMassimo De Micheli
Massimo De Micheli
FBFrancesco Bandello
Francesco Bandello
GFGiulio Ferrari
Giulio Ferrari
To quantify the role of aging and sex in corneal nerve morphology and function and to identify cellular and molecular mechanisms involved in corneal nerve aging in male and female mice. This study included young (8-week-old) and old (52-week-old) C57BL/6N male and female mice. Corneal nerve function was measured using eye wiping and Cochet-Bonnet tests. Corneal nerve density was analyzed after β3-tubulin staining in the sub-basal nerve plexus, the vertical nerve projections, and the superficial nerve terminals. Neuronal and neuroinflammatory markers were quantified in the trigeminal ganglia using immunofluorescence and real-time PCR. Aging significantly reduces nerve density and the corneal nociceptive response (P < 0.0001). Mechanical sensitivity was decreased in male mice (P < 0.0001), but not in females. Female mice showed milder nerve fiber degeneration compared to males (P = 0.0453). Moreover, we identified an age-dependent decrease of substance P-positive neurons in the ophthalmic branch of the trigeminal ganglion (P = 0.0003), which was milder in females (P = 0.0005). Gene expression analysis in the trigeminal ganglion revealed a higher expression of neuroprotective and pro-regenerative markers in female mice. Immunofluorescence analysis revealed an age-dependent increase in the uptake of leukocytes in the trigeminal ganglion (P = 0.0068). M2 anti-inflammatory macrophage numbers were preserved in aging females versus males (P = 0.0008). Aging was associated with sensory corneal neuropathy, altered sensory abnormalities, and neuroinflammation. Interestingly, female mice appeared to be protected from nerve degeneration compared to males.